You are here:Home-Research Areas-Cancer-Breast Cancer

Request The Product List ofBreast Cancer Breast Cancer

Cat. No. Product Name CAS No. Information
PC-62000

Enobosarm

841205-47-8

Enobosarm (GTx-024, MK-2866, Ostarine) is a selective androgen receptor modulator (SARM) for the treatment of conditions such as muscle wasting and osteoporosis.

Breast Cancer

Phase 2 Clinical

PC-61022

CC-671

1618658-88-0

CC-671 is a potent, selective, dual TTK (Mps1)/CLK2 inhibitor with IC50 of 5/3 nM, respectively; weakly inhibits DYRK3, DYRK1A, PHKG, DYRK1B, and CLK1 with IC50 of 0.1-0.3 uM, and displays excellent kinase selectivity (7/235 kinases > 80% inhibition at 3 uM); inhibits autophosphorylation of TTK at T686 or phosphorylation of SR protein 75 with IC50 of 0.057 and 0.549 uM in Cal-51 cells; demonstrates strong single agent in vivo efficacy in multiple TNBC xenograft models without significant body weight loss.

Breast Cancer

Preclinical

PC-70084

Pyrotinib

1269662-73-8

Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50 of 13/38 nM, respectively; displays high selectivity in a panel of different kinases such as KDR, c-Kit, PDGFRβ, c-Src and c-Met (c-Src with an IC50 of 790 nM, and others >3,000 nM); exhibits robust anti-tumor effects on HER2-overexpressing xenograft models and sufficiently safety windows in animals as well as favorable pharmacokinetic properties in human.

Breast Cancer

Phase 3 Clinical

PC-70083

Pyrotinib maleate

1397922-61-0

Pyrotinib maleate (SHR-1258 maleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50 of 13/38 nM, respectively; displays high selectivity in a panel of different kinases such as KDR, c-Kit, PDGFRβ, c-Src and c-Met (c-Src with an IC50 of 790 nM, and others >3,000 nM); exhibits robust anti-tumor effects on HER2-overexpressing xenograft models and sufficiently safety windows in animals as well as favorable pharmacokinetic properties in human.

Breast Cancer

Phase 3 Clinical

PC-45734

Elacestrant dihydrochloride

1349723-93-8

Elacestrant (RAD-1901) is a novel, orally bioavailable small-molecule selective estrogen receptor degrader (SERD); inhibits ERα expression in MCF-7 cells (IC50=0.6 nM); induces the degradation of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth of multiple PDX models.

Breast Cancer

Phase 2 Clinical

PC-45733

Elacestrant

722533-56-4

Elacestrant (RAD-1901) is a novel, orally bioavailable small-molecule selective estrogen receptor degrader (SERD); inhibits ERα expression in MCF-7 cells (IC50=0.6 nM); induces the degradation of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth of multiple PDX models.

Breast Cancer

Phase 2 Clinical

PC-42921

MSI-1436

186139-09-3

An non-competitive, allosteric inhibitor of PTP1B with Ki of 0.6 uM for PTP1B1-405; antagonizes HER2 signaling, inhibits tumorigenesis in xenografts and abrogates metastasis in the NDL2 mouse model of breast cancer

Breast Cancer

Phase 1 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com